Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06506292
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-11
Brief Title:
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced GastricGastroesophageal Junction Cancer GCGEJC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced GastricGastroesophageal Junction Cancer GCGEJC
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric canceradenocarcinoma of the gastroesophageal junction
Detailed Description:
Gastric cancer is the fifth most common cancer in the world and ranks fourth in mortality Radical surgery is the main treatment for resectable gastric cancer For patients with progressive gastric cancer especially those with stage IIIB and IIIC their 5-year overall survival OS rate after radical surgery is still difficult to exceed 50 Although D2 radical surgery and postoperative adjuvant chemotherapy have significantly improved the prognosis of patients with progressive gastric cancer the recurrence rate is still as high as 5080 Several therapeutic approaches have been established to reduce the risk of recurrence and improve long-term survival including perioperative chemotherapy adjuvant chemotherapy and adjuvant radiotherapy The effect of adding targeted therapies andor immune checkpoint inhibitors ICIs to neoadjuvantadjuvant therapies is currently being studied While multiple programmed death 1 PD-1 inhibitors have been approved for firstthird line treatment of unresectablemetastatic gastric cancer However the role of immune checkpoint inhibitors in resectable gastric cancer remains unclear and is being investigated in various clinical trials
We conducted this study with 8 cycles of perioperative treatment with adebrelimab in combination with XELOX chemotherapy regimen and adebelizumab maintenance therapy up to 1 year To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric canceradenocarcinoma of the gastroesophageal junction
We conducted this study with 8 cycles of perioperative treatment with adebrelimab in combination with XELOX chemotherapy regimen and adebelizumab maintenance therapy up to 1 year To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric canceradenocarcinoma of the gastroesophageal junction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None